Literature DB >> 7714917

Effect of persistent mouse hepatitis virus infection on MHC class I expression in murine astrocytes.

J Correale1, S Li, L P Weiner, W Gilmore.   

Abstract

Neurotropic strains of mouse hepatitis virus (MHV) have been used extensively for the study of viral pathogenesis in the central nervous system (CNS), serving as models for human neurological diseases such as multiple sclerosis (MS). MHV strains A59 and JHMV both cause acute and chronic encephalomyelitis and demyelination in susceptible strains of mice and rats. In acute disease, CNS damage is most likely the result of lytic infection in neurons and oligodendrocytes, and death can be prevented by the adoptive transfer of Class I-restricted CD8+ T cells. However, in later stages of the disease induced by some MHV strains, virus tends to be restricted to astrocytes in a nonlytic infection, and the immune response appears to contribute to CNS damage. These data lead us to suggest that the astrocyte may play a central role in the neuropathogenesis of MHV infection. Consistent with this possibility, A59 has been reported to induce the expression of Class I molecules of the major histocompatibility complex (MHC) in glial cells following infection in vivo and in vitro. In this communication, we have examined the influence of persistent infection by both A59 and JHMV on MHC Class I expression in primary murine astrocytes. Persistence was characterized by the presence of intracellular viral antigen and mRNA in the absence of detectable infectious virus particles. Under these conditions, JHMV, but not A59, inhibited constitutive expression of the H-2 Kb molecule, with the magnitude of inhibition increasing with postinfection time. A59 was not able to induce Class I during persistence, presumably due to the lack of infectious virus particles. Class I expression was restored by the addition of gamma-interferon (IFN-gamma) to astrocytes persistently infected with either A59 or JHMV. Thus, Class I inhibition is not a permanent consequence of JHMV persistence, and persistence does not interfere with normal signalling pathways for Class I induction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714917      PMCID: PMC7167169          DOI: 10.1002/jnr.490400103

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  67 in total

1.  Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Brief report.

Authors:  J Lecomte; V Cainelli-Gebara; G Mercier; S Mansour; P J Talbot; G Lussier; D Oth
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Tumor necrosis factor induces expression of MHC class I antigens on mouse astrocytes.

Authors:  E Lavi; A Suzumura; D M Murasko; E M Murray; D H Silberberg; S R Weiss
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain.

Authors:  F M Hofman; R I von Hanwehr; C A Dinarello; S B Mizel; D Hinton; J E Merrill
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

Review 4.  Peptides naturally presented by MHC class I molecules.

Authors:  H G Rammensee; K Falk; O Rötzschke
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes.

Authors:  A Suzumura; E Lavi; S R Weiss; D H Silberberg
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

6.  Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared.

Authors:  D K Male; G Pryce; C C Hughes
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

7.  Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus.

Authors:  J O Fleming; S A Stohlman; R C Harmon; M M Lai; J A Frelinger; L P Weiner
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

8.  Induction of MHC class I antigens on glial cells is dependent on persistent mouse hepatitis virus infection.

Authors:  E Lavi; A Suzumura; E M Murray; D H Silberberg; S R Weiss
Journal:  J Neuroimmunol       Date:  1989-04       Impact factor: 3.478

9.  Monoclonal antibodies to the matrix (E1) glycoprotein of mouse hepatitis virus protect mice from encephalitis.

Authors:  J O Fleming; R A Shubin; M A Sussman; N Casteel; S A Stohlman
Journal:  Virology       Date:  1989-01       Impact factor: 3.616

10.  Mouse hepatitis virus A59 increases steady-state levels of MHC mRNAs in primary glial cell cultures and in the murine central nervous system.

Authors:  J L Gombold; S R Weiss
Journal:  Microb Pathog       Date:  1992-12       Impact factor: 3.738

View more
  5 in total

1.  Viral induction of central nervous system innate immune responses.

Authors:  J D Rempel; L A Quina; P K Blakely-Gonzales; M J Buchmeier; D L Gruol
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 2.  Animal modeling of lower urinary tract dysfunction associated with multiple sclerosis: Part I: Justification of the mouse model for MS research.

Authors:  Ramalakshmi Ramasamy; Phillip P Smith
Journal:  Neurourol Urodyn       Date:  2021-03-14       Impact factor: 2.696

3.  T cell mediated suppression of neurotropic coronavirus replication in neural precursor cells.

Authors:  Warren C Plaisted; Jason G Weinger; Craig M Walsh; Thomas E Lane
Journal:  Virology       Date:  2013-12-12       Impact factor: 3.616

4.  Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis.

Authors:  Sanghee Lee; Balachandar Nedumaran; Joseph Hypolite; Brian Caldwell; Michael C Rudolph; Anna P Malykhina
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

Review 5.  Selection of and evasion from cytotoxic T cell responses in the central nervous system.

Authors:  S Perlman; G F Wu
Journal:  Adv Virus Res       Date:  2001       Impact factor: 9.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.